Agilent Acquires Biocare Medical for $950 Million to Expand Cancer Diagnostics Portfolio
核心洞察
Agilent Technologies (搜索) announced a $950 million all-cash acquisition of Biocare Medical (搜索), a global leader in immunohistochemistry and molecular pathology solutions for cancer diagnostics.
Biocare has demonstrated strong financial performance with annual double-digit revenue and profit growth since 2021, generating over $90 million in revenue in 2025.
The acquisition expands Agilent's pathology portfolio with complementary IHC antibody, reagent and instrument capabilities, expected to be accretive to growth and margins in Year 1.
Agilent Technologies (搜索) has entered into a definitive agreement to acquire Biocare Medical (搜索), a global leader in clinical pathology solutions, for $950 million in an all-cash transaction. The acquisition, announced March 9, 2026, represents a strategic expansion of Agilent's pathology portfolio through the addition of Biocare's specialized antibody, reagent and instrument business.
Biocare Medical (搜索) has established itself as a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. The company maintains more than 300 specialized antibodies and proven R&D capabilities.
Strong Financial Performance Drives Acquisition
The acquisition comes after a period of significant growth for Biocare under the ownership of investor group led by Excellere Partners (搜索) and GHO Capital Partners (搜索) LLP. Since 2021, Biocare has achieved annual double-digit revenue and profit growth, generating over $90 million in revenue in 2025.
"The acquisition of Biocare enhances Agilent's pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation," said Agilent President and CEO Padraig McDonnell. "Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders."
Strategic Benefits and Market Expansion
The transaction is expected to deliver multiple strategic advantages for Agilent. The addition of Biocare's complementary IHC antibody, reagent and instrument portfolio enhances Agilent's immunohistochemistry offering and expands its ability to serve a broad range of pathology labs across clinical and research settings. Biocare brings proven, efficient new-product innovation capabilities that strengthen Agilent's capability to develop and commercialize new IVD antibodies.
By combining Agilent's global operations with Biocare's strong U.S. commercial presence, the transaction creates a stronger platform to better serve a broader base of research and clinical customers. The combined company will be well positioned to meet diverse testing and throughput needs while accelerating the expansion of Biocare's antibody portfolio through Agilent's resources and capabilities.
Financial Impact and Integration Timeline
The deal is expected to be accretive to Agilent's top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent's EPS approximately 12 months following close.
"The acquisition by Agilent is an exciting milestone for Biocare," said Luis de Luzuriaga, CEO of Biocare. "By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve."
The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group.
Private Equity Success Story
Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners (搜索) and GHO Capital respectively, highlighted their successful partnership with Biocare's management team. "Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today," they stated in a joint statement.
The private equity firms emphasized Biocare's development into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. They expressed satisfaction in finding the right strategic partner in Agilent, which can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare's customers worldwide.